Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a first-in-class medication that activates two appetite-regulating hormone pathways simultaneously instead of one. SURMOUNT trials showed 20-25% average body weight loss (up to 22.5% at max dose), making it the most effective injectable weight loss medication available. NPRA approved in Malaysia August 2025. Weekly injection.
What is Tirzepatide?
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It is the first medication that simultaneously activates two incretin hormone receptors — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Every other GLP-1 medication on the market (semaglutide, liraglutide, dulaglutide) only targets one of these receptors. Tirzepatide targets both.
This dual mechanism translates directly to clinical results. In head-to-head trials against semaglutide (the previous gold standard), tirzepatide produced significantly greater weight loss across all dose levels. The SURMOUNT trial series — the largest obesity drug trials ever conducted — showed average weight loss of 20-25% of body weight, with some participants losing over 25%. To put this in perspective: these results approach what gastric sleeve surgery achieves, but without surgery.
Tirzepatide received FDA approval in May 2022 for type 2 diabetes (as Mounjaro) and in November 2023 for chronic weight management (as Zepbound). In Malaysia, it received NPRA approval in August 2025, making it legally available through licensed doctors.
The molecule itself is a synthetic peptide — a single 39-amino acid chain engineered to activate both the GIP and GLP-1 receptors with a bias toward GIP activation. It incorporates a C20 fatty diacid moiety that enables once-weekly dosing by binding to albumin and extending the half-life to approximately 5 days.
How It Works (Dual Mechanism)
Understanding why tirzepatide outperforms single-target GLP-1 medications requires understanding what GIP adds to the equation:
GLP-1 pathway (shared with semaglutide): Activates GLP-1 receptors in the hypothalamus (appetite suppression), gut (delayed gastric emptying), and pancreas (enhanced insulin secretion). This is the pathway that semaglutide uses alone. It reduces hunger, slows digestion, and improves blood sugar control.
GIP pathway (unique to tirzepatide): GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone. Traditionally, GIP was considered less important than GLP-1 for weight management. Tirzepatide changed this understanding. GIP receptors are found in adipose (fat) tissue, brain, bone, and pancreas. When activated, GIP enhances fat metabolism, improves lipid handling, increases energy expenditure, and provides additional appetite suppression through brain pathways that GLP-1 does not fully access.
Synergistic effect: The GIP and GLP-1 pathways are not simply additive — they are synergistic. GIP activation appears to amplify the appetite-suppressing effects of GLP-1 and adds a direct effect on fat tissue metabolism. The dual mechanism also improves tolerability — some evidence suggests GIP activation may partially offset GLP-1-mediated nausea, which is why some patients report fewer GI side effects on tirzepatide than semaglutide despite greater weight loss.
Enhanced insulin sensitivity: Tirzepatide produces greater improvements in insulin sensitivity than semaglutide alone. GIP directly signals pancreatic beta cells to produce insulin in a glucose-dependent manner, while also improving how fat cells respond to insulin signalling. This dual-pathway insulin improvement is why tirzepatide shows superior HbA1c reduction in diabetes patients.
Improved lipid profile: GIP receptor activation in adipose tissue enhances triglyceride clearance and improves cholesterol handling. Clinical trials consistently show greater improvements in triglycerides, LDL cholesterol, and HDL cholesterol with tirzepatide compared to semaglutide.
Mounjaro vs Zepbound
The molecule is identical. Mounjaro and Zepbound are the same drug (tirzepatide) at the same doses, made in the same factories by Eli Lilly. The only difference is the approved indication on the label and packaging. In Malaysia, Mounjaro is the more practical choice — it is the formulation that received NPRA approval and is available through specialist clinics.
Tirzepatide vs Semaglutide (Head-to-Head)
SURPASS-2 (head-to-head): The SURPASS-2 trial directly compared tirzepatide against semaglutide 1mg in type 2 diabetes patients. Tirzepatide 15mg produced significantly greater weight loss (-12.4 kg vs -6.2 kg) and HbA1c reduction (-2.07% vs -1.86%). While this trial used the lower semaglutide dose (1mg, not the 2.4mg weight-management dose), the margin was substantial enough that most experts believe tirzepatide would still outperform semaglutide at comparable maximal doses.
SURMOUNT Trial Results
SURMOUNT-1 (n=2,539): Adults with obesity, no diabetes. 72 weeks. Results by dose: 5mg lost 15.0%, 10mg lost 19.5%, 15mg lost 20.9% of body weight (vs 3.1% placebo). Over half of participants on the 10mg and 15mg doses lost more than 20% of their body weight. More than one-third on 15mg lost over 25%.
SURMOUNT-2 (n=938): Adults with obesity AND type 2 diabetes. 72 weeks. 10mg lost 12.8%, 15mg lost 14.7%. Exceptional for a diabetic population where weight loss is inherently harder.
SURMOUNT-3 (n=579): Participants first completed a 12-week intensive lifestyle intervention (lost ~6% body weight), then started tirzepatide or placebo. Those on tirzepatide 15mg lost an additional 18.4% on top of the lifestyle-phase loss. Total weight loss from baseline: approximately 24.3%. Demonstrates that combining lifestyle intervention with tirzepatide produces the best possible results.
SURMOUNT-4 (n=670): Withdrawal study. Participants who stopped tirzepatide after 36 weeks regained approximately 14% of their lost weight over the following 52 weeks (vs 2.5% continued loss in those who stayed on medication). Confirms the importance of continued treatment for weight maintenance.
Titration Schedule
Tirzepatide uses a 6-step titration schedule to reach the full therapeutic dose. Each step is 4 weeks minimum. Rushing this process dramatically increases GI side effects:
2.5mg per week (starting dose)
Initiation dose. Not a therapeutic dose for weight loss — the purpose is to let your GI system adapt. Mild appetite effects may be noticed. Some nausea is possible but typically mild.
5mg per week
First therapeutic dose. Meaningful appetite suppression begins. Early weight loss starts — typically 2-4 kg in this phase. The 5mg dose alone produces significant results (15% weight loss in SURMOUNT-1). Some patients stay at this dose long-term.
7.5mg per week
Intermediate step. Appetite suppression intensifies. Weight loss accelerates. GI side effects, if present, typically peak during this transition and settle within 1-2 weeks.
10mg per week
Strong therapeutic dose. 19.5% average weight loss at this dose in trials. Significant metabolic improvements visible in bloodwork. Many patients find their optimal balance of efficacy and tolerability here.
12.5mg per week
Intermediate step toward maximum dose. Additional weight loss above 10mg. Some patients experience renewed GI effects during this escalation that settle over 1-2 weeks.
15mg per week (maximum dose)
Full therapeutic dose. 20.9% average weight loss in trials. Maximum metabolic benefit. Not all patients need to reach this dose — your doctor will determine the optimal maintenance dose based on your response, side effects, and goals.
Month-by-Month: What to Expect
Initiation (2.5mg)
Subtle changes. Appetite may decrease slightly. Most users do not see significant scale movement yet — this is the adaptation phase. Some mild nausea in the first 48 hours after injection. Weight loss: 0-2 kg.
First Results (5mg)
Appetite suppression becomes clear. Food portions naturally shrink. Sugar cravings reduce. The "food noise" — constant thinking about what to eat — begins to quiet. Weight loss: 3-5 kg cumulative. Clothes start fitting noticeably looser.
Acceleration (7.5-10mg)
Visible weight loss that others notice. 6-10 kg cumulative. Energy levels improve as metabolic function normalises. Blood sugar stabilizes. Fasting insulin improves. Many users report improved sleep quality and reduced joint pain from weight reduction.
Major Transformation (10-15mg)
12-18 kg weight loss for most users. Bloodwork improvements become dramatic — lower triglycerides, improved cholesterol, reduced inflammatory markers, normalized fasting glucose. Waist circumference drops 10-15 cm. Physical activity becomes easier and more enjoyable. Relationship with food fundamentally transforms.
Continued Progress (Maintenance dose)
15-25% total body weight loss for most users at optimal doses. Rate of loss naturally decreases as the body approaches a new metabolic equilibrium. Focus shifts to maintaining results, optimizing body composition through resistance training, and establishing sustainable lifestyle habits that complement the medication.
Who Benefits from Tirzepatide?
Significant Weight Goals (20+ kg)
If you need to lose 20-50 kg, tirzepatide provides the highest efficacy of any injectable medication — approaching surgical outcomes without the operating room
Semaglutide Plateau or Non-Responders
If you have been on semaglutide and results have stalled or were insufficient, tirzepatide's additional GIP pathway can break through — documented in clinical practice
Severe Metabolic Dysfunction
Type 2 diabetes with obesity, severe insulin resistance, metabolic syndrome — tirzepatide's dual mechanism addresses multiple pathways simultaneously
Executive Health Optimization
High-achievers who want the most effective medication available and are willing to invest in maximum results. One weekly injection, maximum impact
Cardiovascular Risk Reduction
While CV outcomes data is pending (SURPASS-CVOT), the degree of weight loss and metabolic improvement strongly suggests cardiovascular benefit
Those Who Value Cutting-Edge Science
First-in-class dual mechanism, massive trial program, backed by Eli Lilly — for patients who want the latest and most evidence-backed treatment available
Side Effects & Safety
Very common (15-30%): Nausea, diarrhea, decreased appetite. Similar to semaglutide but some data suggests GIP activation may partially buffer the nausea — discontinuation rates due to GI events in SURMOUNT-1 were low (4.3-7.1%). Most GI effects occur during dose escalation and resolve at stable doses.
Common (5-15%): Constipation, vomiting, abdominal pain, dyspepsia (indigestion), injection site reactions (minor redness/itching). Fatigue during initial weeks as the body adjusts to reduced caloric intake.
Less common (1-5%): Hypoglycemia (mainly in diabetics on concomitant insulin or sulfonylureas), hair thinning (associated with rapid weight loss, not the drug itself — usually temporary), acid reflux.
Rare but monitored: Gallbladder events (gallstones, cholecystitis — as with all rapid weight loss), acute pancreatitis (very rare), potential thyroid C-cell effects (theoretical concern from animal studies, monitored in trials with no signal in humans).
Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Pregnancy or breastfeeding. History of severe hypersensitivity to tirzepatide. History of pancreatitis requires careful evaluation. These are screened during your consultation.
Malaysia Availability
NPRA Status: Tirzepatide (Mounjaro) received National Pharmaceutical Regulatory Agency (NPRA) approval in August 2025 for type 2 diabetes. This makes it legally prescribable by licensed Malaysian doctors.
Current availability: Limited to specialist endocrinology clinics, private hospitals (Pantai, Gleneagles, Prince Court, Sunway Medical), and selected weight management centres. General practitioners generally do not stock or prescribe tirzepatide yet — the supply chain is still developing.
Off-label weight management: Like Ozempic/semaglutide, Mounjaro is officially indicated for diabetes but is prescribed off-label for weight management. This is standard practice globally. Your doctor evaluates appropriateness based on your individual health profile.
Pricing: RM1,200-3,000 per month depending on dose tier (lower doses during titration are less expensive). This is comparable to or slightly less than semaglutide at equivalent efficacy levels.
Supply considerations: Global demand for tirzepatide has been extremely high. Supply in Malaysia can be intermittent. Peak Protocol maintains relationships with specialist pharmacies to ensure consistent access for our patients.
Peak Protocol connects you with specialists who have prescribing experience with tirzepatide, understand the titration protocol, and can manage the transition from other GLP-1 medications if needed. Start with a WhatsApp consultation to discuss whether tirzepatide is right for your goals.
Frequently Asked Questions
How do I get tirzepatide in Malaysia?
You need a prescription from a licensed Malaysian doctor. Tirzepatide is mainly available through specialist clinics and private hospitals. Most GPs do not prescribe it. Peak Protocol connects you with experienced doctors who can evaluate your suitability and prescribe tirzepatide if appropriate.
Is tirzepatide legal in Malaysia?
Yes. Tirzepatide (Mounjaro) received NPRA approval in August 2025. It is legal when prescribed by a licensed doctor and dispensed from a licensed pharmacy. All medications through Peak Protocol are sourced from authorized pharmaceutical channels.
Should I choose tirzepatide or semaglutide?
Tirzepatide produces greater weight loss on average (20-25% vs 15-20%) due to its dual mechanism. Choose tirzepatide if you want maximum weight loss, have significant weight to lose (20+ kg), or have plateaued on semaglutide. Choose semaglutide if you prefer a more established medication with cardiovascular outcomes data (SELECT trial), wider availability in Malaysia, or a lower starting cost. Your doctor will recommend based on your goals, health profile, and budget.
Can I switch from semaglutide to tirzepatide?
Yes. Switching is common in clinical practice, especially for patients who have plateaued on semaglutide. The transition is straightforward — you stop semaglutide and start tirzepatide at the beginning of the titration schedule (2.5mg). Your doctor will time the switch to ensure continuous coverage without overlap.
How much weight will I lose on tirzepatide?
Clinical trials show average weight loss of 20-25% of body weight at the highest dose (15mg) over 72 weeks. For a 100kg person, that is 20-25 kg. Over half of participants on 10-15mg doses lost more than 20%. Individual results vary based on dose achieved, starting weight, diet, exercise, and metabolic factors.
How long does titration take?
Minimum 20 weeks to reach the maximum 15mg dose (5 dose escalation steps, 4 weeks each). Some patients take longer if GI side effects require extended time at a particular dose. Many patients find optimal results at 10mg and do not need to go to 15mg. Your doctor will individualize the titration based on your response.
Is tirzepatide better than bariatric surgery?
Tirzepatide approaches but does not quite match the average weight loss of gastric sleeve surgery (25-30%) or gastric bypass (30-35%). However, it avoids surgical risks, is reversible, requires no recovery period, and has a more favorable side effect profile. For patients who are not candidates for or do not want surgery, tirzepatide is the closest pharmaceutical alternative. Some patients use tirzepatide before surgery to reduce surgical risk, or instead of surgery altogether.
What happens if tirzepatide is out of stock?
Global supply can be intermittent. If your current dose is temporarily unavailable, your doctor may recommend staying at a lower available dose temporarily, or briefly switching to semaglutide as a bridge. Peak Protocol maintains relationships with multiple specialist pharmacies to minimize supply disruptions for our patients.
Does tirzepatide have cardiovascular benefits like semaglutide?
The SURPASS-CVOT trial (dedicated cardiovascular outcomes trial for tirzepatide) is ongoing. Semaglutide has proven CV benefits from the SELECT trial (20% MACE reduction). While tirzepatide is expected to show similar or superior CV outcomes given its greater metabolic improvements, this has not yet been confirmed by a dedicated outcomes trial. This is one reason some doctors still prefer semaglutide for patients with significant cardiovascular risk.